A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amilomotide (Primary) ; Umibecestat (Primary)
Indications Alzheimer's disease; Dementia
Focus Therapeutic Use
Acronyms Generation S1
Sponsors Amgen; Novartis; Novartis Pharmaceuticals

Most Recent Events

06 Apr 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
31 Jul 2020 Results presented at the Alzheimer's Association International Conference 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight